Acta Scientific Medical Sciences (ASMS)(ISSN: 2582-0931)

Review Article Volume 7 Issue 11

Therapeutic Efficacy of Nanoparticles in the Treatment of Diabetes Mellitus. An Overview

Madiha M Al Sulimani1*, Abdulkader M Shaikh Omar1,2, Salim M El Hamidy1,2 and Isam M Abu Zeid1,2

1Department of Biological Sciences, Faculty of Science, King Abdulaziz University, Jeddah, Saudi Arabia
2Princess Dr. Najla Bint Saud Al-Saud Center for Excellence Research in Biotechnology, King Abdulaziz University, Jeddah, Saudi Arabia

*Corresponding Author: Madiha M Al Sulimani, Department of Biological Sciences, Faculty of Science, King Abdulaziz University, Jeddah, Saudi Arabia.

Received: September 27, 2023; Published: October 26, 2023

Abstract

Nanotechnology can provide new solutions for diabetes management by developing more accurate .and less invasive methods for glucose monitoring and insulin delivery. For example, nanoparticles can be used as contrast agents to help diagnose type 1 diabetes at an early stage, or as carriers for oral insulin formulations that can bypass the digestive enzymes and reach the bloodstream. Nanosensors can also be implanted or worn on the skin to measure glucose levels continuously and wirelessly, reducing the need for painful finger pricks and frequent testing. Moreover, nanotechnology can enable smart insulin delivery systems that can automatically release insulin in response to variations in blood glucose levels, mimicking the function of a healthy pancreas. This review aims to highlight the recent advances and challenges of nanotechnology in diabetes treatment and prevention.

 Keywords: Nanotechnology; Diabetes; Insulin; Nanopump; Artificial Pancreas

References

  1. Bowonsomsarita W., et al. "Four-week induction of type 2 diabetes mellitus in rats by streptozotocin and high-fat diet". Chulalongkorn Medical Journal4 (2021): 449-457.
  2. Ogurtsova K., et al. "IDF Diabetes Atlas: global estimates for the prevalence of diabetes for 2015 and 2040". Diabetes Research and Clinical Practice 128 (2017): 40-50.
  3. Weisman A., et al. "Evolving trends in the epidemiology, risk factors, and prevention of type 2 diabetes: A review". Canadian Journal of Cardiology 34 (2018): 552-564.
  4. Lagopati N and Pavlatou EA. "Nanotechnology in Diabetes Management". Interventions Obesity Diabetes1 (2021): 419-424.
  5. Othman MS., et al. "The Potential Role of Zinc Oxide Nanoparticles in MicroRNAs Dysregulation in STZ-Induced Type 2 Diabetes in Rats". Biological Trace Element Research 197 (2020): 606-618.
  6. Mohammad NK. "Prevention and Management of Diabetes and its Complications by Unani Herbal Medicine - A Review". Endocrinology and Metabolism International Journal4 (2017): 1-5.
  7. Behera A., et al. "Nanomedicine and type 2 diabetes: A review". Journal of Pharmacy Research3 (2018): 370-377.
  8. Okur ME., et al. "Diabetes Mellitus: a review on pathophysiology, current status of oral pathophysiology, current status of oral medications and future perspectives". ACTA Pharmaceutica Sciencia1 (2017): 61-82.
  9. Ojha A., et al. "Current perspective on the role of insulin and glucagon in the pathogenesis and treatment of type 2 diabetes mellitus". Clinical Pharmacology: Advances and Applications 11 (2019): 57-65.
  10. Veiseh O., et al. "Managing diabetes with nanomedicine: Challenges and opportunities". Nature Reviews Drug Discovery 14 (2015): 45-57.
  11. Italiya KS., et al. "Scalable self-assembling micellar system for enhanced oral bioavailability and efficacy of lisofylline for treatment of type-I diabetes". Molecular Pharmaceutics12 (2019): 4954-4967.
  12. Li Y., et al. "Advances in oral peptide drug nanoparticles for diabetes mellitus treatment". Bioactive Materials 15 (2022): 392-408.
  13. Pereira C., et al. "Targeting membrane transporters and receptors as a mean to optimize orally delivered biotechnological based drugs through nanoparticle delivery systems". Current Pharmaceutical Biotechnology7 (2014): 650-658.
  14. Ito S., et al. "Oral coadministration of Zn-insulin with D-form small intestine-permeable cyclic peptide enhances its blood glucose-lowering effect in mice". Molecular Pharmaceutics4 (2021): 1593-1603.
  15. Abdulmalek SA and Balbaa M. "Synergistic effect of nano-selenium and metformin on type 2 diabetic rat model: diabetic complications alleviation through insulin sensitivity, oxidative mediators and inflammatory markers". pone 14.8 (2019): 220-779.
  16. Rashid R., et al. "Nanotechnology and Diabetes Management: Recent Advances and Future Perspectives". Application of Nanotechnology in Biomedical Sciences (2020): 99117.
  17. Mahmoud EA., et al. "Silver/chitosan/ascorbic acid nanocomposites ameliorate diabetic nephropathy in the model of type 1 diabetes". GSC Biological and Pharmaceutical Sciences3 (2021): 91-102.
  18. Rezaei-kelishadi M., et al. "Control, Management and Treatment of Diabetes Using Modern Drug Delivery Systems and Special Properties of Nanoparticles". Journal of Biology and Today's World 9 (2014): 206-211.
  19. Taguchi M., et al. "Nanomaterial-mediated biosensors for monitoring glucose". Journal of Diabetes Science and Technology2 (2014): 403-411.
  20. Duggan EW., et al. "Perioperative hyperglycemia management: An update". Anesthesiology3 (2017): 547-560.
  21. Bahendeka S., et al. "EADSG guidelines: Insulin storage and optimisation of injection technique in diabetes management". Diabetes Therapy: Research, Treatment and Education of Diabetes and Related Disorders 2 (2019): 341-366.
  22. Chen C., et al. "Current and emerging technology for continuous glucose monitoring". Sensors1 (2017): 1-19.
  23. Samant PP and Prausnitz MR. "Mechanisms of sampling interstitial fluid from skin using a microneedle patch". Proceedings of the National Academy of Sciences of the United States of America18 (2018): 4583- 4588.
  24. Srivastava R., et al. "Smart tattoo glucose biosensors and effect of coencapsulated antiinflammatory agents". Journal of Diabetes Science and Technology1 (2011): 76-85.
  25. Mannino GC., et al. "Pharmacogenetics of type 2 diabetes mellitus, the route toward tailored medicine". Diabetes/Metabolism Research and Reviews3 (2019): 1-20.
  26. Wilson J., et al. "Layer-by-layer assembly of a conformal nanothin PEG coating for intraportal islet transplantation". Nano Letter 8 (2008): 1940-1948.
  27. Opara A., et al. "Islet cell encapsulation - Application in diabetes treatment". Experimental Biology and Medicine 246 (2021): 2570-2578.
  28. Wiggins S., et al. "Nanotechnology approaches to modulate immune responses to cell based therapies for type 1 diabetes". Journal of Diabetes Science and Technology 14 (2020): 212-225.
  29. Teramura Y and Iwata H. "Surface modification of islets with PEG-lipid for improvement of graft survival in intraportal transplantation". Transplantation 88 (2009): 24-30.
  30. Simos YV., et al. "Trends of nanotechnology in type 2 diabetes mellitus treatment". Asian Journal of Pharmaceutical Sciences 16 (2020): 62-76.
  31. Sharma G., et al. "Nanoparticle based insulin delivery system: the next generation efficient therapy for type 1 diabetes". Journal of Nanobiotechnology1 (2015): 1-13.
  32. Shah RB., et al. "Insulin delivery methods: Past, present and future". International Journal of Pharmaceutical Investigation1 (2016): 1-9.
  33. Yang NJ and Hinner MJ. "Getting across the cell membrane: An overview for small molecules, peptides, and proteins. Methods in Molecular Biology". Clifton N J 1266 (2015): 29-53.
  34. Patra JK., et al. "Nano based drug delivery systems: Recent developments and future prospects". Journal of Nanobiotechnology 1 (2018): 1-33.
  35. Mansoor S., et al. "Polymer-based nanoparticle strategies for insulin delivery". Polymers (2019): 1-27.
  36. Wagner AM., et al. "Designing the new generation of intelligent biocompatible carriers for protein and peptide delivery". Acta Pharmaceutica Sinica B 8.2 (2018): 147-164.
  37. Marques C., et al. "How the lack of chitosan characterization precludes implementation of the safe-by-design concept". Frontiers in Bioengineering and Biotechnology 8 (2020): 1-12.
  38. Homayun B., et al. "Challenges and recent progress in oral drug delivery systems for biopharmaceuticals". Pharmaceutics3 (2019): 1-29.
  39. Pegoraro C., et al. "Transdermal drug delivery: from micro to nano". Nanoscale6 (2012): 1881-1894.
  40. Ensign LM., et al. "Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers". Advanced Drug Delivery Reviews6 (2012): 557-570.
  41. Yu J., et al. "Microneedle-array patches loaded with hypoxia-sensitive vesicles provide fast glucose-responsive insulin delivery". Proceedings of the National Academy of Sciences27 (2015): 8260-8265.
  42. Archana S and Sundaramoorthy B. "Review on biofouling prevention using nanotechnology". Journal of Entomology and Zoology Studies 7 (2019): 640-648.
  43. Gu Z., et al. "Injectable nano-network for glucose-mediated insulin delivery". ACS nano 5 (2013): 4194-4201.
  44. Li C., et al. "Glucose and H 2 O 2 dual-sensitive nanogels for enhanced glucoseresponsive insulin delivery". Nanoscale 18 (2019): 9163-9175.
  45. Shapiro AM., et al. "Strategic opportunities in clinical islet transplantation". Transplantation 10 (2005): 1304-1307.
  46. Abazari MF., et al. "PCL/PVA nanofibrous scaffold improve insulin-producing cells generation from human induced pluripotent stem cells". Gene 671 (2018): 50-57.
  47. Naser M., et al. "Nanotechnology in Diagnosis and Treatment of Diabetes Mellitus: Review". International Journals of Sciences and High Technologies 24 (2020): 586-596.
  48. Xiao X., et al. "Endogenous reprogramming of alpha cells into beta cells, induced by viral gene therapy, reverses autoimmune diabetes". Cell Stem Cell1 (2018): 78-90.
  49. Gallego-Perez D., et al. "Topical tissue nano-transfection mediates non-viral stroma reprogramming and rescue". Nature Nanotechnology10 (2017): 974-979.
  50. Bajracharya R., et al. "Recent advancements in non-invasive formulations for protein drug delivery". Computational and Structural Biotechnology Journal 17 (2019): 12901308.
  51. Ibrahim M., et al. "Inhalation drug delivery devices: technology update". Medical Devices (2015): 131-139.
  52. Xia Y., et al. “Preparation, characterization, and pharmacodynamics of insulin-loaded fumaryl diketopiperazine microparticle dry powder inhalation". Drug Delivery1 (2019): 650-660.
  53. El Sherbiny IM., et al. "Inhaled nano-and microparticles for drug delivery". Global Cardiology Science and Practice2 (2015): 1-14.
  54. Souto EB., et al. "Nanoparticle delivery systems in the treatment of diabetes complications". Molecules 23 (2019): 1-29.
  55. Jaafar MH and Hamid KA. "Chitosan-coated alginate nanoparticles enhanced absorption profile of insulin via oral administration". Current Drug Delivery 7 (2019): 672-686.
  56. Liang HF., et al. "Novel Method Using a Temperature-Sensitive Polymer (Methylcellulose) to Thermally Gel Aqueous Alginate as a pH-Sensitive Hydrogel". Bio macromolecules 5 (2004): 1917-1925.
  57. Smyth S and Heron A. "Diabetes and obesity: the twin epidemics". Med1 (2006): 75- 80.
  58. Barkam S., et al. "Fabricated micro-nano devices for in vivo and in vitro biomedical applications". Wiley Interdisciplinary Reviews-Nanomedicine and Nanobiotechnology 6 (2013): 544-568.
  59. McAdams BH and Rizvi AA. "An overview of insulin pumps and glucose sensors for the generalist". Journal of Clinical Medicine 1 (2016): 1-17.
  60. Shirin A., et al. "Optimal regulation of blood glucose level in type I diabetes using insulin and glucagon". Plos One 3 (2019): 1-23.
  61. Berney T., et al. "From islet of Langerhans transplantation to the bioartificial pancreas". Presse Med4 (2022): 1-11.
  62. Liu D., et al. "The smart drug delivery system and its clinical potential". Theranostics9 (2016): 1306-1323.
  63. Malhotra P and Shahdadpuri N. “Nano robots for continuous blood glucose diagnosis”. International Journal of Trend in Scientific Research and Development6 (2019): 10231028.

Citation

Citation: Madiha M Al Sulimani., et al. “Therapeutic Efficacy of Nanoparticles in the Treatment of Diabetes Mellitus. An Overview”.Acta Scientific Medical Sciences 7.11 (2023): 108-117.

Copyright

Copyright: © 2023 Madiha M Al Sulimani., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.




Metrics

Acceptance rate30%
Acceptance to publication20-30 days
Impact Factor1.403

Indexed In





News and Events


  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is June 25, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue"
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US